secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001558370-23-017418
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q3 2023 net loss $14.3M vs $18.9M YoY; cash $118.2M funds into mid-2025
--------------------------------------------------------------------------------

- Cash and securities $118.2M at Sep 30 2023, down $41.7M from Dec 31 2022; expects funding into mid-2025.
- Net loss $14.3M for Q3 2023 vs $18.9M for Q3 2022; narrowed loss due to lower R&D and G&A costs.
- R&D expenses $11.0M (down from $13.5M); G&A $4.6M (down from $5.7M).
- Phase 1b updates for NC410 and NC762, and NC525 Phase 1a update expected by year end 2023.
- Selected LNCB74 (B7-H4 ADC) from LegoChem collaboration; presented data on NC605 and NC181.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/0001558370-23-017418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/nxtc-20231102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer